In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Sophie J. Bakri, MD, discusses outcomes from the FARETINA-AMD study of faricimab as a treatment for age-related macular degeneration.
Data from the IRIS Registry was used to examine faricimab treatment patterns. Patients with a diagnosis of AMD, one or more faricimab injections from February 2022 to June of 2023, 6 months or more of follow-up and two or more best documented visual acuity measures on or after the first injection were included in the analysis. The researchers examined the interval extension of